You are here: AU  Staff Departments  iNANO News and events News Show

NNF, Hallas-Møller Emerging Investigator

2019.01.09 | Yvonne Eskildsen-Helmond

The Novo Nordisk Foundation - Hallas-Møller Emerging Investigator

Deadline: January 9, 2019

PURPOSE

To support and strengthen the development of young and promising research leaders, and promote Danish fundamental research at a high international level, the Novo Nordisk Foundation seeks to support the starting group leaders with ambitious projects relevant to understanding the human organism and/or basal mechanisms underlying health and disease.
 

The Emerging Investigator grant is for talented starting group leaders. The grant is intended for either senior postdocs who have matured to the point of starting their own research group or junior group leaders in the early phase of establishing his or her own research group. Applicants should have a maximum of 2-3 years of group leader experience at the time of the project start. Applicants are expected to have first-authored peer-reviewed research papers with a high impact. Ideally, after their PhD degree, applicants should have approximately 4-8 years of subsequent research experience (parental leave excluded).

 

ELIGIBILITY

  • Applicants should, at the time of application, be at the level of senior postdoc, senior researcher, assistant or associate professor (time limited/not tenured). Importantly they should be starting independent researchers. Applicants who are already established independent group leaders with two or more senior authorships should apply for Hallas-Møller Ascending Investigator.
  • Applicants must, during the project, be employed and have their research group in Denmark.
  • The project must be anchored at a university, hospital or other non-profit research institution in Denmark.
  • Recipients of this grant must contribute to the pre-graduate teaching environment at their host institution. An Emerging Investigator grant must not be used to cover a teaching substitute for the applicant.

Read more here

Funding opportunities
Tags: Novo Nordisk, Biomedical Research
4871 / i35